In a scientific breakthrough that aids our understanding of the internal wiring of immune cells, researchers at Monash University in Australia have cracked the code behind IKAROS, an essential protein for immune cell development and protection against pathogens and cancer.
A new study led by Yale Cancer Center researchers at Yale School of Medicine found that while the initiation of immunotherapy near the end of life has increased over time, a closer look at the benefit and value of these therapies in patients with advanced-stage disease is needed.
A type of immune cell can help predict which patients may benefit most from cancer immunotherapies, researchers from King’s College London, Guy’s and St Thomas’ Hospital Trust, and the Francis Crick Institute have found.
حدد الباحثون والمتعاونون في مايو كلينك بروتينًا تفرزه الخلايا المناعية والذي قد يقوم بدورٍ رئيسيٍ في ظهور مرضالتصلُّب الجانبي الضموري، المعروف أيضًا باسم مرض لو غيريغ. ووجد الفريق أيضًا أن العلاج التعديلي المناعي الذي يقوم بعملية إِحْصار للبروتين يمكنه استعادة الوظيفة الحركية في النماذج قبل السريرية. وتشير النتائج إلى أن البروتين، المعروف باسم أ5 إنتغرين (الذي يُنطق ألفا 5 إنتغرين)، هو مستهدف علاجي محتمل لعلاج مرض التصلُّب الجانبي الضموري.
Los investigadores y colaboradores de Mayo Clinic han identificado una proteína expresada en células inmunitarias que podría desempeñar un rol clave en el desarrollo de la esclerosis lateral amiotrófica (ELA), también conocida como enfermedad de Lou Gehrig. El equipo también descubrió que un tratamiento inmunomodulatorio que bloquea la proteína era capaz de restaurar la función motriz en modelos preclínicos. Los hallazgos indican que la proteína, conocida como integrina α5 (pronunciado integrina alfa 5), es un posible blanco terapéutico para la ELA.
Pesquisadores e colaboradores da Mayo Clinic identificaram uma proteína que é expressa por células imunológicas que pode desempenhar uma função importante no desenvolvimento daesclerose lateral amiotrófica (ELA), também conhecida como doença de Lou Gehrig. A equipe também descobriu que um tratamento imunomodulador que bloqueia a proteína conseguiu restaurar a função motora em modelos pré-clínicos. As descobertas sugerem que a proteína, conhecida como integrina α5 (pronunciada como integrina alfa 5), é um possível alvo terapêutico para ELA.
Cedars-Sinai Cancer investigators have discovered a new way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant.
With the rise in machine learning applications and artificial intelligence, it's no wonder that more and more scientists and researchers are turning to supercomputers. Supercomputers are commonly used for making predictions with advanced modeling and simulations. This can be applied to climate research, weather forecasting, genomic sequencing, space exploration, aviation engineering and more.
Researchers from the National University of Singapore (NUS) devise a simple and innovative way to directly identify and sort the immune cells involved in cell-mediated cytotoxicity.
Immune cells play an active and intimate role in directing the growth of human lung tissue during development, researchers find, revolutionising our understanding of early lung development and the role of immune cells outside of immunity.
Using lab-made cells, Harvard Med researchers identify how the immune system neutralizes herpesvirus.
Study maps, for the first time, the maneuvers used by virus and host in the cell nucleus.
Findings could inform design of new treatments for herpes and other viruses that replicate in the same way.
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy treatments based on its proprietary Alluminox™ platform, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held January 8-11, 2024.
By monitoring changes in circulating tumor DNA (ctDNA) among 30 patients treated with immunotherapies for metastatic non-small cell lung cancers, researchers were able to determine molecular response — the clearance of tumor genetic material in the bloodstream.
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center say a new combination of antibody therapies produced a ‘surprisingly high’ response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.
Investigators from the C.S. Mott Center for Human Growth and Development at the Wayne State University School of Medicine reported today in a publication in Cancer Immunology Research the characterization of a novel therapeutic approach capable of restoring immune surveillance and providing long-term protection against ovarian cancer tumors.
A study led by researchers at Sylvester Comprehensive Cancer Center suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins. Downloadable video is available.
One to two weeks after contracting COVID, the SARS-CoV-2 virus generally becomes undetectable in the upper respiratory tract. But does that mean that it is no longer present in the body? To find out, a team from the Institut Pasteur specialized in HIV, in collaboration with a French public research institute, the Alternative Energies and Atomic Energy Commission (CEA), conducted a study on lung cells in an animal model.
According to new predictions by La Jolla Institute for Immunology (LJI) researchers, if the new SARS-CoV-2 Pirola variant wants to evade T cells, it isn't doing a very good job.
Researchers at the University of Turku, Finland, have uncovered how the new bexmarilimab therapy alters the function of immune cells so that they can infiltrate the tumour in cancer patients who do not respond to any other current therapies.
A special report published today in the Association for Diagnostics & Laboratory Medicine’s (ADLM’s, formerly AACC’s) The Journal of Applied Laboratory Medicine describes the design, operations, and methodology of the COVID Immunity Study, a large-scale scientific study by ADLM that took place in September 2021.
Realizing the full potential of macrophage therapies relies on being able to see what these cellular allies are doing inside our bodies, and a team of Penn State researchers may have developed a way to watch them do their thing.
Researchers have discovered that misreading of therapeutic mRNAs by the cell’s decoding machinery can cause an unintended immune response in the body. They have identified the sequence within the mRNA that causes this to occur and found a way to prevent ‘off-target’ immune responses to enable the safer design of future mRNA therapeutics.
Researchers at the Francis Crick Institute, working with Imperial College London, King’s College London and University of Cambridge, have shown that an influx of water and ions into immune cells allows them to migrate to where they’re needed in the body.
Researchers have discovered the novel mechanism that underlies a previously reported observation that infection by group A Streptococcus bacteria reduces the risk of later developing Type 1 diabetes.
In some diseases, the underlying processes can start years before a diagnosis is made. A new study finds that people who later develop multiple sclerosis (MS) are more likely to have conditions like depression, constipation and urinary tract infections five years before their MS diagnosis than people who do not develop MS.
As one of the most insidious diseases in the world, cancer has few treatments that work to eradicate it completely. Now, a new ground-breaking approach pioneered by two researchers working at the University of Missouri’s Roy Blunt NextGen Precision Health building shows promising results in preventing lung cancer caused by a carcinogen in cigarettes — a discovery that immunologists Haval Shirwan and Esma Yolcu rank among the most significant of their careers.
A study that assesses the effects of hypochlorous acid (HOCI), commonly known as bleach, as it is generated during the immune response of a cell (phagocytosis) when fighting a common fungal pathogen, Candida albicans, reveals that HOCI is a potent killing agent. The laboratory finding is highlighted in the journal mBio.
La inmunoterapia aprovecha el sistema inmunitario del organismo para combatir el cáncer. El tratamiento con linfocitos T con receptor quimérico para el antígeno (tratamiento con linfocitos T-CAR) es una forma de inmunoterapia en la que los profesionales de atención médica extraen las células T de una persona (conocidas como linfocitos que participan en la respuesta del sistema inmunitario) y las modifican genéticamente para que produzcan receptores quiméricos para el antígeno. A continuación, estos linfocitos T-CARse reintroducen en el torrente sanguíneo del paciente, donde se dirigen a las células cancerosas y las destruyen.
العلاج المناعي يسخر جهاز المناعة في الجسم لمحاربة السرطان. العلاج بالخلايا التائية المستقبلة للمستضدات الخيمرية (العلاج بخلايا CAR-T) هو شكل من أشكال العلاج المناعي الذي يقوم فيه أخصائيو الرعاية الصحية بإزالة الخلايا التائية للشخص — خلايا الدم البيضاء المعروفة باسم الخلايا اللمفية التي تشارك في استجابة الجهاز المناعي — وتعديلها وراثيًا لإنتاج مستقبلات المستضد الخيمرية (CARs). يتم بعد ذلك حقن الخلايا التائية المستقبلة للمستضدات الخيمرية (CAR-T) مرة أخرى في مجرى دم المريض، حيث تستهدف الخلايا السرطانية وتقتلها.
A new study from researchers at Wake Forest University School of Medicine shows that dopamine release in the human brain plays a crucial role in encoding both reward and punishment prediction errors.
Researchers, led by University of Melbourne’s Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), discovered distinct mechanisms controlling different types of immune cells, and found that, by precisely targeting these mechanisms, they could selectively eliminate ‘problematic cells’ and reshape the skin's immune landscape.
Incorporating navy beans into the diet of colorectal cancer survivors has the potential to positively impact both gut and host health by modulating markers linked to obesity and disease, according to new research from The University of Texas MD Anderson Cancer Center.
SEATTLE — Nov. 30, 2023 — The 65th Annual Meeting & Exposition of the American Society of Hematology (ASH) will take place in San Diego, Calif. and online Dec. 9-13.Below are highlights of Fred Hutchinson Cancer Center research to be presented and experts available to comment on news.
Adding a modular chimeric cytokine receptor to CAR T cells increased their efficacy. Learn how this modular system could improve brain and solid tumor therapy.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have found certain immune cells can still fight cancer even when the cancer cells lack an important protein that the immune system relies on to help track down cancer cells.
Hospital germs and pathogens are not always transmitted directly from person to person. They can also spread via germ-contaminated surfaces and objects.
Traditional cancer treatments such as chemotherapy and radiation can come with collateral damage. In the process of killing cancer, the treatments harm normal cells, too, leading to both short- and long-term side effects. Even today’s targeted drugs and immunotherapy can have effects on normal tissues.